









Markets
/
Stocks
/
nasdaq-phat
/

Phathom Pharmaceuticals Inc

PHAT

11.750USD

+0.750+6.82%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

823.73MMarket Cap

LossP/E TTM



Phathom Pharmaceuticals Inc

11.750

+0.750+6.82%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

70 / 175

Overall Ranking

196 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

21.375

Target Price

+94.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Growing

The company is in a growing phase, with the latest annual income totaling USD 55.25M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 69.09.

Fairly Valued

The company’s latest PE is -2.36, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 61.93M shares, decreasing 25.00% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.79M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.09.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.06, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 39.50M, representing a year-over-year increase of 439.36%, while its net profit experienced a year-over-year increase of 17.10%.

Score

Industry at a Glance

Previous score

8.06

Change



Financials

6.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.06

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.46

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -2.36, which is -21.86% below the recent high of -1.84 and -1.92% above the recent low of -2.40.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 70/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.44, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Phathom Pharmaceuticals Inc is 20.00, with a high of 29.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

21.375

Target Price

+94.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Phathom Pharmaceuticals Inc

PHAT

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.61, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 12.62 and the support level at 9.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.77

Change

-0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.431

Neutral

RSI(14)

54.941

Neutral

STOCH(KDJ)(9,3,3)

27.431

Neutral

ATR(14)

0.702

High Vlolatility

CCI(14)

-64.685

Neutral

Williams %R

57.870

Sell

TRIX(12,20)

0.596

Sell

StochRSI(14)

85.241

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

11.410

Buy

MA10

11.909

Sell

MA20

11.940

Sell

MA50

10.274

Buy

MA100

8.297

Buy

MA200

7.287

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 88.60%, representing a quarter-over-quarter decrease of 9.98%. The largest institutional shareholder is The Vanguard, holding a total of 2.79M shares, representing 3.93% of shares outstanding, with 3.02% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

11.97M

+18.44%

Medicxi Ventures (UK) LLP

7.46M

Abingworth Management Limited

3.50M

Invesco Advisers, Inc.

3.35M

-0.55%

BlackRock Institutional Trust Company, N.A.

2.91M

-5.47%

The Vanguard Group, Inc.

Star Investors

2.77M

-0.03%

Ensign Peak Advisors, Inc.

2.51M

-0.51%

683 Capital Management LLC

1.45M

+40.98%

New Enterprise Associates (NEA)

1.96M

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 2.98, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.